Effect Of Treatment On The Prognosis Of Patients With Advanced Lung Cancer Maintenance Pemetrexed

Background: lung cancer is the most common fatal type of cancer [1] worldwide,and the patients with non small cell lung cancer(NSCLC)account for about eighty-five percent [2] of the patients with lung cancer.Data from foreign studies show that more than 50% of the lung cancer patients have been found in the late stage of the disease in the first visit,and the vast majority of the patients have distant metastasis,and then they have lost the opportunity to receive surgical treatment.[3].Therefore,in the treatment of advanced lung cancer,the most important part is chemotherapy.And the most important treatment for advanced lung cancer chemotherapy is the regimen of platinum containing drugs and other chemotherapy regimen [4].The recommended cycle of the standard first-line chemotherapy is 4-6 cycles.After the end of the first-line chemotherapy course,the patient's condition is evaluated.Maintenance therapy is chosen as a follow-up treatment.At present,the maintenance therapy has been applied to the clinical,and as a treatment of advanced lung cancer,to improve the quality of life of the patients,prolong the survival time of the patients and control the progress of the disease as the purpose of [5].At present,there are a variety of first-line chemotherapy schemes.There are different drugs for different pathological types,such as pemetrexed,gemcitabine,docetaxel and so on.The most common chemotherapy scheme is pemetrexed + cisplatin(AP)[6],which is the most common treatment in the maintenance treatment.The example of seeing.Pemetrexed,as an anticancer drug,is a drug that can inhibit folic acid metabolism at multiple targets.After entering cells,it can be transformed into polyglutamic acid through a series of reaction processes.In varying degrees,dihydrofolate reductase,glycylribonucleoside Methoyl transferase and thymidine can be made in different degrees.The activity of a variety of enzymes such as acid synthase is inhibited and the synthesis of purine and pyrimidine is blocked.The mitosis of cancer cells and the replication process of DNA are greatly affected,so that the proliferation of tumor cells is inhibited [7,8].Therefore,pemetrexed can be used as a first-line combined platinum chemotherapy drug,and it can also be used as a single drug for maintenance treatment.Purpose:The purpose of this study is that there is no clear guide to the use of pemetrexed in the maintenance of treatment.In order to further clarify the clinical significance of pemetrexed in the application of pemetrexed in patients with advanced lung adenocarcinoma and the dosage and method of pemetrexed,this clinical trial should focus on the treatment of lung adenocarcinoma in our center.Patients who were treated with pemetrexed were observed to observe the efficacy of pemetrexed for chemotherapy in the treatment of advanced non small cell carcinoma(NSCLC),and to control the tumor to the maximum,improve the quality of life and prolong the survival period.Methods: 50 patients with lung adenocarcinoma and stage III B/ IV in the middle of January 2015-2017-2017 year were selected and 24 cases of advanced NSCLC patients received disease control after 4 cycles of pemetrexed + cisplatin(AP regimen)chemotherapy were selected as the control group,and 26 cases were screened for first-line chemotherapy.Patients were given pemetrexed alone on the twenty-first day to maintain chemotherapy as the observation group until the disease progressed or the patient died for special reasons.The main observation was PFS,OS and adverse reactions.Results: 26 cases of advanced patients enrolled in this screening completed the 137 cycle of maintenance chemotherapy,TTP was 5.3 months,the progression free survival PFS was 7.25 � 1.37 months,and the total survival time was 11.4 months.24 patients who had not used pemetrexed for maintenance treatment were PFS for 3.18 +�1.12 months,the total survival time OS was 8.13 months and P < 0.05.It was of clinical significance.Results:The results of the clinical trial can prove that pemetrexed can significantly prolong the total survival and no progress survival period of the patients.It can be used in clinical practice.During pemetrexed maintenance treatment,the main adverse reactions were leukocyte reduction,fatigue and rash,but patients could tolerate it.Conclusion: the application of pemetrexed to maintain chemotherapy after first-line chemotherapy is safe and reliable in patients with advanced NSCLC,which can obviously prolong the patient's PFS and OS,and the adverse reaction can be tolerated.